Deborah L. Burkhart

This paper identifies the EZH2-TTP-mTORC1 axis as a driver of phenotypic plasticity and therapeutic vulnerability in prostate cancer, showing that combined inhibition of EZH2 and PI3K/mTORC1 improves anti-tumor activity.

This study identifies MYBL2 as a master regulator of phenotypic plasticity in prostate cancer and shows CDK2 inhibition as a potential therapeutic strategy for MYBL2-driven tumors.

This paper introduces SESORRS, a technique combining SERRS and SORS for in vivo tumor imaging, showing improved SNR and faster acquisition of deep-seated tumor data.